Fig. 3: Deepness of response by cetuximab-free interval. | British Journal of Cancer

Fig. 3: Deepness of response by cetuximab-free interval.

From: Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Fig. 3

The rate of deepness of response >0% is higher in the long- than in the short CFI group (55% vs. 13%, respectively, p = 0.003). The CFIs of three patients with a rate of DpR of >0% in the short CFI group were 338, 181 and 176 days, respectively, from the right of patients. *Patients who discontinued first-line cetuximab-containing treatment due to reasons other than progressive disease. CFI cetuximab-free interval, DpR deepness of response.

Back to article page